JP4050317B2 - Ｉｌ−１０含有医薬組成物 - Google Patents

Ｉｌ−１０含有医薬組成物 Download PDF

Info

Publication number
JP4050317B2
JP4050317B2 JP50824697A JP50824697A JP4050317B2 JP 4050317 B2 JP4050317 B2 JP 4050317B2 JP 50824697 A JP50824697 A JP 50824697A JP 50824697 A JP50824697 A JP 50824697A JP 4050317 B2 JP4050317 B2 JP 4050317B2
Authority
JP
Japan
Prior art keywords
wounds
wound
pharmaceutical composition
healing
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50824697A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11510505A (ja
JPH11510505A5 (2
Inventor
ファーガソン，マーク・ウィリアム・ジェイムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of JPH11510505A publication Critical patent/JPH11510505A/ja
Publication of JPH11510505A5 publication Critical patent/JPH11510505A5/ja
Application granted granted Critical
Publication of JP4050317B2 publication Critical patent/JP4050317B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Eye Examination Apparatus (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP50824697A 1995-08-09 1996-08-08 Ｉｌ−１０含有医薬組成物 Expired - Fee Related JP4050317B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9516287.1 1995-08-09
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines
PCT/GB1996/001930 WO1997005894A1 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10

Publications (3)

Publication Number Publication Date
JPH11510505A JPH11510505A (ja) 1999-09-14
JPH11510505A5 JPH11510505A5 (2) 2004-09-09
JP4050317B2 true JP4050317B2 (ja) 2008-02-20

Family

ID=10778967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50824697A Expired - Fee Related JP4050317B2 (ja) 1995-08-09 1996-08-08 Ｉｌ−１０含有医薬組成物

Country Status (13)

Country Link
US (2) US6387364B1 (2)
EP (1) EP0871473B1 (2)
JP (1) JP4050317B2 (2)
AT (1) ATE229814T1 (2)
AU (1) AU719089B2 (2)
CA (1) CA2229078C (2)
DE (1) DE69625516T2 (2)
DK (1) DK0871473T3 (2)
ES (1) ES2187665T3 (2)
GB (1) GB2304047A (2)
PT (1) PT871473E (2)
WO (1) WO1997005894A1 (2)
ZA (1) ZA966744B (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69716460T2 (de) * 1996-12-04 2003-06-26 Renovo Ltd., Manchester Wundheilung und behandlung von fibrose
AU6045198A (en) * 1997-02-05 1998-08-25 Schering Corporation Use of il-4 and/or il-10 to treat proliferative glomerulonephritis
CA2384076A1 (en) * 1999-09-08 2001-03-15 Schering Corporation Novel uses of mammalian ccr6 receptors and related reagents
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US20030148952A1 (en) * 2001-10-18 2003-08-07 Crombleholme Timothy M. Methods and materials for the recruitment of endothelial cells
NZ588743A (en) * 2003-07-15 2012-05-25 Univ Bar Ilan Use of a protein kinase C (PKC) alpha inhibitor for treating inflammation of the skin
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
GB0500643D0 (en) 2005-01-13 2005-02-23 Renovo Ltd Medicaments
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
CA2664304C (en) * 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
AU2007319811A1 (en) 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
CN102755649A (zh) * 2007-07-30 2012-10-31 希尔洛有限公司 药物组合物及相关方法
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2008343840A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
CA2710386A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
US20110021618A1 (en) * 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
EP3348281B1 (en) 2008-12-17 2023-07-05 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
CN102325789A (zh) * 2009-02-24 2012-01-18 希尔洛有限公司 用于治疗痤疮和其它病症的内脂素治疗药物
WO2012112791A1 (en) 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
WO2012135842A2 (en) * 2011-03-31 2012-10-04 President And Fellows Of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
CN104768567B (zh) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
US10098929B2 (en) 2013-08-02 2018-10-16 Children's Hospital Medical Center Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
DE3889479T2 (de) 1987-02-27 1994-12-22 Eastman Kodak Co Mit Nieder-pI-Protein beschichtete Membranstruktur und Verfahren zu ihrer Herstellung und Verwendung.
JPH0611706B2 (ja) * 1989-01-20 1994-02-16 ザ ユニバーシティ オブ メルボルン フィブリン溶解
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
EP0502080A4 (en) * 1989-11-21 1993-02-10 The University Of Melbourne Anti-inflammatory compositions and methods
JP3616392B2 (ja) 1990-04-11 2005-02-02 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド アクチン結合性化合物の療法的使用
DK0566661T3 (da) * 1991-01-10 1996-07-01 Schering Corp Anvendelse af IL-4 til forstærkning af den reparative fase af sårheling og -reparation og til forstærkning af helingen af inficerede sår og sår hos diabetiske pattedyr
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
AU8647991A (en) 1991-08-26 1993-03-16 State of Oregon Acting by and Through The State of Board of Higher Education on Behalf of The Oregon Health Sciences University, The Keratinocyte-derived conditioned medium as a source of growth factors
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
WO1994027640A1 (en) * 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury
FI960353A7 (fi) 1993-07-26 1996-01-26 Schering Corp Ihmisen interleukiini-10:n agonistit ja antagonistit
US5972335A (en) * 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
JPH11501506A (ja) * 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
GB9516012D0 (en) * 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases

Also Published As

Publication number Publication date
GB9516287D0 (en) 1995-10-11
US20020128447A1 (en) 2002-09-12
AU6666096A (en) 1997-03-05
JPH11510505A (ja) 1999-09-14
US7052684B2 (en) 2006-05-30
WO1997005894A1 (en) 1997-02-20
EP0871473A1 (en) 1998-10-21
CA2229078C (en) 2010-04-20
ATE229814T1 (de) 2003-01-15
DE69625516D1 (de) 2003-01-30
GB2304047A (en) 1997-03-12
DE69625516T2 (de) 2003-09-25
US6387364B1 (en) 2002-05-14
DK0871473T3 (da) 2003-04-14
CA2229078A1 (en) 1997-02-20
PT871473E (pt) 2003-03-31
AU719089B2 (en) 2000-05-04
ZA966744B (en) 1998-02-09
EP0871473B1 (en) 2002-12-18
ES2187665T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
JP4050317B2 (ja) Ｉｌ−１０含有医薬組成物
US4808402A (en) Method and compositions for modulating neovascularization
Bessis et al. The type II decoy receptor of IL‐1 inhibits murine collagen‐induced arthritis
JP4083794B2 (ja) 創傷の治癒
JP4102437B2 (ja) アクチビンおよびインヒビン刺激因子を含有する医薬組成物
US5202118A (en) Method for promoting wound healing using IL-1
JP2007119497A (ja) インターフェロン−ガンマスティミュレーター含有医薬組成物
EP2718456B1 (en) Mitigation of cutaneous injury with il-12
EP2572724A1 (de) Behandlung von Fibrosen und Lebererkrankungen
JP4189030B2 (ja) 瘢痕の形成を減少するためのベータグリカンの使用
DE3883252T2 (de) Örtliche wundheilmittel, die interleukin-1-proteine enthalten.
US20090285775A1 (en) Treatment of wounds using il-17b
DE69209051T2 (de) Verwendung von il-4 zur verstärkung von wundheilung und besserung und zur heilung von infizierten wunden und wunden bei diabetischen säugetieren
WO2000057902A1 (en) Method and pharmaceutical composition for wound healing
EP2089050A2 (en) Il- 17b for use in wound healing
DE69916022T2 (de) Methode zur Verwendung von IL-11 zur Verstärkung der zellvermittelten Immunität zur Behandlung verschiedener viraler und parasitärer Infektionen und Krebs
WO1995007710A1 (en) Remedy for wound
US20080159979A1 (en) Treatment of wounds using il-17b
DE60019921T2 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock
AU747598B2 (en) Pharmaceutical composition containing stimulators of interferon-gamma
SAHARA et al. The Effect of GM-CSF of the Inhibition of Contraction of Excisional Wounds Caused by Bacterial Contamination
HK1024419A (en) Healing of wounds or fibrotic disorders using at least one agent against a growth factor
WO2000068267A1 (en) LOW-DOSE IL-1β-INDUCED PHOTORECEPTOR CELL RESCUE WITHOUT RETINAL DYSPLASIA

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20061212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071129

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101207

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101207

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111207

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111207

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121207

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131207

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees